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Abstract: The Epstein–Barr virus (EBV) is associated with lymphomas and carcinomas. For some of
these, the adoptive transfer of EBV specific T cells has been therapeutically explored, with clinical
success. In order to avoid naturally occurring EBV specific autologous T cell selection from every
patient, the transgenic expression of latent and early lytic viral antigen specific T cell receptors (TCRs)
to redirect T cells, to target the respective tumors, is being developed. Recent evidence suggests
that not only TCRs against transforming latent EBV antigens, but also against early lytic viral gene
products, might be protective for the control of EBV infection and associated oncogenesis. At the
same time, these approaches might be more selective and cause less collateral damage than targeting
general B cell markers with chimeric antigen receptors (CARs). Thus, EBV specific TCR transgenic T
cells constitute a promising therapeutic strategy against EBV associated malignancies.
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1. Introduction of EBV and Its Oncogenesis
The Epstein–Barr virus (EBV) was discovered in 1964, and was the first human tumor virus [1,2].
It is still, to date, the most potent pathogen to transform human B cells into immortalized lymphoblastoid
cell lines (LCLs) in vitro [3]. Despite this high oncogenic potential and its classification as a WHO class
I carcinogen [4–6], most adult humans carry EBV asymptomatically. Indeed, more than 95% of the
human adult population is persistently infected with EBV, and the infection programs in healthy virus
carriers are the same as have been found in EBV associated malignancies [7,8]. The default program of
B cell infection by EBV is the growth transforming latency III, expressing six nuclear antigens (EBNAs)
and two latent membrane proteins (LMPs), together with viral non-translated small RNAs (EBERs) and
miRNAs (Figure 1). This viral gene expression pattern is also found in EBV associated post-transplant
lymphoproliferative disease (PTLD), HIV associated immunoblastic lymphoma, some diffuse large B
cell lymphomas (DLBCL) and LCLs [9]. It is thought to drive EBV infected naïve B cells, in which
latency III is found in healthy EBV carriers [10], into differentiation to memory B cells, the reservoir of
long-term viral persistence [11]. The next step after latency III in this differentiation path is thought
to be the germinal center differentiation of B cells, and EBV reduces its latent gene transcription to
EBNA1 and the two LMPs plus non-translated RNAs to facilitate the survival of infected B cells [12].
Indeed, this latency II program can be found in the germinal center B cells of healthy virus carriers.
At this differentiation stage, uninfected B cells acquire somatic mutations to increase antigen affinity of
their B cell receptor [13]. Unfortunately, the same mechanism also favors pro-oncogenic mutations like
c-myc transloctions, and EBV associated Hodgkin’s and Burkitt’s lymphoma are thought to originate
from this differentiation stage [14]. Hodgkin’s lymphoma expresses latency II, and in most Burkitt’s
lymphomas, only EBNA1 is expressed as the sole viral protein. Via germinal center differentiation,
EBV infected B cells can reach the memory B cell pool for long-term persistence. Persistence can also
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be reached without latency III, albeit less efficiently and probably via the direct infection of memory
B cells [15]. In memory B cells, no viral proteins, but only non-translated RNAs are expressed, in so
called latency 0 [11]. During their homeostatic proliferation, EBNA1 is transiently expressed in latency
I that is also found in Burkitt’s lymphoma [16]. From latency 0 and I, the infectious particle producing
lytic EBV replication can be induced upon plasma cell differentiation, presumably after B cell receptor
engagement [17].
Figure 1. Epstein–Barr (EBV) associated B cell lymphomas emerge from different stages of EBV infection.
Latency III with the indicated latent viral gene expression can be found in naïve B cells of healthy
virus carriers, from which post-transplant lymphoproliferative disease (PTLD) and diffuse large B
cell lymphoma (DLBCL) are thought to emerge. Reduced latency II viral gene expression is found
in germinal center B cells, giving rise to Hodgkin-Reed-Sternberg (HRS) cells in Hodgkin’s disease
(HD), as well as Burkitt’s lymphoma, with further down-regulation of LMP1 and 2. EBV persists in
memory B cells without viral protein expression (latency 0) or transient EBNA1 expression (latency I),
during homeostatic proliferation. Lytic EBV replication occurs after plasma cell differentiation from
this persistence pool. The immediate early lytic transactivator BZLF1 kicks-off infectious virus particle
production with immediate early, early and late lytic viral gene expression. Primary effusion lymphoma
(PEL) is a plasmacytoma with elevated lytic EBV replication compared to other virus associated
lymphomas. This figure was created in part with modified Servier Medical Art templates, which are
licensed under a Creative Commons Attribution 3.0 unported license: https://smart.servier.com.
This lytic replication can then be amplified through lytic replication in mucosal epithelial cells for
efficient viral shedding into the saliva that transmits EBV to new hosts [18]. EBV associated epithelial
cell cancers are thought to originate from this infection, but carry abnormal latent EBV gene expression.
For example, nasopharyngeal carcinoma (NPC) often expresses latency II and EBV associated gastric
carcinoma sometimes even latency I [19,20]. Therefore, all oncogenic programs of EBV infection
are present in healthy virus carriers. While PTLDs are often oligoclonal and primarily driven by
EBV oncogenes, the EBV associated malignancies with latency I and II expression programs require
additional somatic mutations and are therefore often monoclonal. Accordingly, PTLD development
can be rapid, often occurring during the first year after organ transplantation, while Burkitt’s and
Hodgkin’s lymphoma occur at later timepoints after transplantation [21]. In contrast, in HIV infected
individuals, Burkitt’s and Hodgkin’s lymphoma emerge earlier than latency III immunoblastic
lymphoma [22]. This is best explained by the inverse gradients of immune suppression that are
observed after transplantation and HIV infection. While immune suppression is most pronounced
early after transplantation and late in HIV infection when immunogenic EBV latency III lymphomas
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occur, Hodgkin’s and Burkitt’s lymphoma, with restricted viral antigen expression, occur late after
transplantation and earlier in HIV infection in the presence of recovered or not yet sufficiently damaged
immune responses. These considerations suggest that efficient immune responses seem to protect us
from EBV associated lymphomas.
2. Immune Control of EBV
This immune control is mainly mediated by cytotoxic lymphocytes, including natural killer
(NK) and CD8+ T cells that expand during symptomatic primary EBV infection, so called infectious
mononucleosis (IM) [23]. Furthermore, the adoptive transfer of EBV specific T cell lines is used to treat
some of the above mentioned EBV associated malignancies, including PTLD, Hodgkin’s lymphoma
and NPC [24–26]. Cytotoxic lymphocytes, predominantly CD8+ T cells, are also identified as the
cornerstones of EBV specific immune control by primary immunodeficiencies that predispose for EBV
associated pathologies [27–29]. The underlying mutations affect genes that are either required for
perforin mediated cytotoxicity, the co-stimulation of cytotoxic lymphocytes, T cell receptor signaling,
generation of cytotoxic lymphocytes or their efficient expansion and survival. In contrast, loss of
type I and II interferons or antibody responses does not seem to predispose for EBV associated
pathologies [28]. Deficiencies in cytotoxic lymphocytes result in continuous immune stimulation
without efficient immune control of EBV and manifest as IM, hemophagocytic lymphohistiocytosis,
lymphoproliferative diseases and virus associated B cell lymphomas. In severe cases, only bone
marrow transplantation provides a valid therapeutic option [29]. In order to understand the functions
of the cytotoxic lymphocyte populations and of molecules that are identified by mutations in primary
immunodeficiencies during EBV specific immune control, mice with reconstituted human immune
systems (HIS mice) are explored [30]. For this purpose, mice that lack murine lymphocytes due to
genetic deficiencies are neonatally reconstituted with human CD34+ hematopoietic progenitor cells
and their human immune system components that develop after three months allow EBV infection,
associated oncogenesis and cell-mediated immune control [30]. In these mice, the contribution of
cytotoxic lymphocytes to EBV specific immune control has been addressed. Protection by CD8+ and
CD4+ T cells, NK cells, NKT cells and γδ T cells has been demonstrated [31–38]. In addition, the
pharmacological inhibition of T cell function by FK506 (tacrolimus), that increases the risk for PTLD
development in transplant patients elevates EBV loads in infected HIS mice and virus associated
lymphoma incidence [39]. Moreover, antibody mediated blocking of the co-receptors 2B4 or PD-1 on T
cells also compromises EBV specific immune control in HIS mice [40,41]. Depending on the viral dose
of infection, an IM like expansion of CD8+ T cells can be induced upon EBV infection, accumulating
PD-1+ CD8+ T cells, with a germinal center homing phenotype reminiscent of tonsillar EBV specific
CD8+ T cells in humans [41–43]. In good agreement with findings in primary immunodeficiency
patients type I interferon and its main producers, plasmacytoid dendritic cells had little effect on EBV
infection in HIS mice [44]. In combination, the above discussed evidence suggests that cytotoxic CD8+
T cells are the most suitable immune compartment to control persistent EBV infection long-term and to
prevent virus associated malignancies.
3. Antigen Specificity of Protective T Cell Responses against EBV
EBV, however, encodes eight latent proteins and more than 80 lytic gene products, all of which are
potential targets for such protective cytotoxic CD8+ T cell responses [45,46]. In order to reestablish
immune control in patients with EBV associated tumors and protect vulnerable populations by
prophylactic vaccination, a subset of these antigens has to be selected to isolate protective T cell clones
or their T cell receptors for adoptive transfer into HLA matched donors, or to incorporate them into
suitable vaccines. Originally, the respective studies primarily focused on the latent EBV antigens that
contain the viral oncogenes and are expressed in the EBV transformed tumor cells. These studies
revealed that healthy EBV carriers primarily recognize EBNA3A, 3B and 3C of latency III and to a
lesser extent EBNA1, EBNA2 and LMP2, but rarely EBNA-LP and LMP1 [45]. In particular, EBNA2
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specific CD8+ T cell responses can kill EBV infected B cells early after virus exposure, due to the
early expression of this latent viral gene product [47]. The less frequent responses often depend on
the presence of distinct major histocompatibility complex (MHC) class I molecules as the presenting
molecules for the respective antigens [48]. In contrast, MHC class II restricted CD4+ T cells recognize a
broad range of latent EBV antigens, with EBNA1 specific CD4+ T cells present in every healthy virus
carrier [49,50]. All latent EBV antigen specific CD8+ and many CD4+ T cells directly recognize LCLs and
can kill them, suggesting protective functions against EBV infection and its pathologies in vivo [51–53].
Among these T cell responses, EBNA1 and/or LMP1 and LMP2 specific T cells have been selectively
isolated or expanded for adoptive transfer into patients with EBV associated malignancies, resulting
in clinical benefits [26,54–56]. Moreover, EBNA1 incorporation into EBV derived virus like particles
or recombinant adenoviruses and modified vaccinia virus Ankara (MVA) induced protection against
infection challenge in mice with reconstituted human immune system components or tumor challenge
in regular mice [57,58]. Therefore, EBNA1, LMP1 and LMP2 specific T cells are favored as protective
entities targeting latent EBV proteins.
However, CD4+ and CD8+ T cells in even higher frequencies than those specific for latent EBV
antigens recognize lytic viral gene products [45]. For example, early lytic EBV antigen specific CD8+ T
cells against single peptide epitopes can constitute up to 40% of all CD8+ T cells in the peripheral blood
of IM patients [59]. For a long time, their protective function was in doubt, because their cytokines most
likely cause IM symptoms [60]. However, recently it was realized that the two early lytic viral Bcl-2
homologues BHRF1 and BALF1 are immediately and transiently expressed early after EBV infection of
B cells, and therefore could be targeted for immune control [61–63]. Moreover, early lytic EBV gene
expression was found to contribute to virus associated tumor formation [7,64,65]. Indeed, such cells
with early lytic EBV infection can be targeted with CD8+ T cells that are specific for the early lytic EBV
antigen BMLF1 [66]. CD8+ T cells of healthy EBV carriers recognize preferentially early lytic EBV
antigens and less late structural proteins [45]. CD4+ T cells recognize, again, a wider spectrum of lytic
antigens including late viral gene products, and such late lytic EBV antigen specific CD4+ T cells have
been found to inhibit EBV associated lymphoma formation in mice [67]. Therefore, also lytic EBV
antigen specific T cells, especially CD8+ T cells that recognize early lytic viral gene products, should be
considered for their protective function against infection and virus associated malignancies.
4. EBV Specific T Cell Receptors in Preclinical Studies
Instead of expanding EBV specific T cells, the receptors of these T cells (TCRs) have been explored
to redirect CD4+ and CD8+ T cell populations, to recognize and eliminate EBV transformed B cells.
Such TCRs have been generated from EBNA3A, EBNA3B, LMP1, LMP2, BRLF1 and BMLF1 specific
CD8+ T cell clones [68–71] (Figure 2).
Unfortunately, T cell lines transgenic for these T cell receptors recognized autologous LCLs only
weakly. This is in part due to limited latent EBV antigen expression in LCLs and even potent CD8+ T
cell clones of healthy EBV carriers can only kill one third of LCLs, even when far outnumbering their
target cells [72]. This low latent EBV antigen expression was proposed to lead only to the presentation
of one copy of an EBNA3C peptide on every third LCL in culture [73]. Additionally, for lytic EBV
antigen recognition, only a small percentage of LCLs are at any given timepoint in lytic replication,
and can be targeted by lytic EBV antigen specific CD8+ T cells [66]. Several strategies have been
explored to improve EBV positive tumor recognition by T cells with EBV specific TCR transgenes.
The recombinant TCRs have been equipped with the co-stimulatory signaling domain of CD28 [69].
However, while the T cells with such an improved EBNA3B specific T cell receptor produced more
IFN-γ in response to autologous LCLs, they did not kill these target cells more efficiently. Furthermore,
different promotors were compared to drive the expression of a LMP2 specific T cell receptor [74].
While the Vβ6.7 promotor was identified to drive highest transgenic T cell receptor expression, the
killing of autologous LCLs was not improved. Nevertheless, tumor progression by adoptive transfer of
the CNE NPC line into nude mice could be significantly attenuated by TCR transgenic T cell transfer.
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As an additional approach, transgenic TCR expression in cord blood T cells was explored, in order
to generate less differentiated EBV specific T cell lines [75]. While LMP2 specific TCR transgenic T
cells with longer telomeres and early differentiation marker expression were obtained, these were not
significantly better in killing EBV derived epitope presenting target cells. Therefore, it was reasoned
that some of the transgenic TCR α and β chains might pair with the endogenous TCR and thereby
dilute redirection for efficient LCL recognition. To counteract this, chimeric TCR were generated,
containing mouse TCR constant regions and the variable domains of TCRs from EBV specific T cell
clones [76]. Although autologous LCL recognition was not compared between LMP2 chimeric and
entirely human TCRs, chimeric TCR transgenic T cells were able to efficiently reject LMP2 expressing
tumor cells in immune compromised mice. CD8+ T cells with LMP2 and BMLF1 specific TCRs of
similar design also efficiently expanded during EBV infection in HIS mice [41]. In these studies, stability
of the murine TCR constant region pairing was improved by introducing an additional disulfide bond
between the TCR α and β chain constant domains. A similar improvement was then chosen for another
LMP2 specific codon optimized TCR [77]. Transgenic T cells with this receptor were able to kill up
to half of co-incubated EBV positive NPC cells and to suppress LMP2 expressing tumor cell growth
in immune compromised mice. More recently, LMP1 has also been targeted with TCR transgenic T
cells [71]. Despite the two decades of development of EBV specific TCRs for transgenic expression,
however, the killing of autologous LCLs remains a challenge and peaks also for this newest TCR at 20%.
Nevertheless, the transfer of LMP1 specific TCR transgenic T cells doubles the survival of immune
compromised mice that have been challenged with LMP1 expressing tumor cells. Thus, despite the
seemingly low level of cytotoxicity against autologous tumor cells that, however, is also observed for
EBV specific T cell clones, transgenic T cell therapy should be developed for clinical application against
EBV associated malignancies.
Figure 2. Available EBV specific T cell receptors (TCRs) target different stages of EBV infection and
associated tumorigenesis. EBV transforms B cells after infection, by establishing latent viral gene
expression from circularized viral genomes. This transforming latent EBV infection is targeted by TCR
recognizing HLA presented EBNA3A, EBNA3B, LMP1 and LMP2. For further tumor growth and
presumably tumor microenvironment conditioning, early lytic EBV infection in a subset of infected
cells is required. This early lytic EBV gene expression is targeted by BRLF1 and BMLF1 specific TCRs.
This figure was created in part with modified Servier Medical Art templates, which are licensed under
a Creative Commons Attribution 3.0 unported license: https://smart.servier.com.
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5. EBV Specific Chimeric Antigen Receptors in Preclinical Studies
A higher level of in vitro cytotoxicity against B cell lymphomas can be achieved with T cells
expressing chimeric antigen receptors (CARs). CAR transgenic T cells targeting CD19, CD20,
CD22 and CD30 were able to kill around 50% of different B cell lymphomas in cell culture [78–80].
The respective CARs usually contain the variable region of antibodies against these B cell surface
markers, a transmembrane domain and the CD3ζ T cell receptor signaling domain, with or without
additional costimulatory signaling domains of CD28 or 4-1BB (CD137) or OX40 (CD134) [81]. These
therapies have provided spectacular clinical results, often with 60% of B cell lymphoma and leukemia
patients in complete remission after treatment [82,83]. However, due to the abundance of target cells,
including both normal and malignant B cells, for the infused CAR transgenic T cells, significant side
effects of cytokine release syndrome and neurotoxicity have also been observed [81]. Moreover, due to
the persistence of B cell targeting CAR transgenic T cells, they could, with time, induce deficiencies in
humoral immune responses when plasma cell-based antibody responses wane and would need to be
replaced by memory B cells. These would then result in vulnerabilities predisposing for respiratory
and gastrointestinal infections, as seen in combined variable immunodeficiency (CVID) patients [84].
In order to avoid these side effects, EBV, instead of B cell specific CARs, would be desirable to target
EBV associated malignancies.
Along these lines, a CAR against LMP1 has been explored against NPC [85,86]. Although a
substantial amount of LMP1 is actually located in endosomes and not accessible on the surface of EBV
associated tumor cells for CAR recognition [87], NPC cells overexpressing LMP1 could be targeted by
T cells transgenic for a LMP1 specific CAR [85,86]. Up to 70% of LMP1 overexpressing NPC cells could
be killed in vitro and growth of these tumor cells could be arrested by the respective CAR expressing
T cells upon transfer into immune compromised mice. A LMP1 specific CAR with CD3ζ and 4-1BB
(CD137) signaling domains was most efficient in controlling tumor growth in vivo [85]. Unfortunately,
these studies leave the question unanswered if EBV associated tumor cells with physiological levels
of LMP1 expression can also be targeted by the viral antigen specific CAR. Nevertheless, both EBV
surface antigen specific CARs and TCRs that are able to detect intracellular EBV antigen expression via
MHC restriction should be further explored to treat EBV associated malignancies.
6. Clinical Development of EBV Specific TCRs and B Cell Specific CARs against EBV Associated
Malignancies
Along these lines, more than 250 clinical trials with CARs targeting common B cell markers,
primarily CD19, are currently registered with ClinicalTrials.gov (www.clinicaltrials.gov). Even among
the trials that clearly indicate EBV associated malignancies as treatment targets, trials with CAR
transgenic T cells outnumber trials with EBV specific TCR transgenic T cells (Table 1).
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Table 1. Selection of clinical trials with transgenic T cell treatments targeting EBV associated malignancies from ClinicalTrials.gov (www.clinicaltrials.gov), that clearly
name EBV positive tumors as one of their indications for enrollment.
Study Name Conditions Interventions Trial Phase Locations
TCR transgenic T cells
EBV-TCR-T Cells for EB Virus Infection After HSCT (NCT04156217) PTLD
HLA-A2, -A11 and -A24 restricted TCRs
expressed in allogeneic donor T cells
Phase 1 Hebei (China)
EBV-TCR-T (YT-E001) for Patients With EBV-positive Recurrent or Metastatic NPC (NCT03648697) NPC
HLA-A2, -A11 and -A24 restricted LMP1, LMP2
and EBNA1 specific TCRs expressed in
autologous T cells
Phase 1/2 Fujian (China)
Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients (NCT03925896) NPC
HLA-A2, -A11 and -A24 restricted LMP2 specific
TCRs expressed in autologous T cells
Phase 1 Guangzhou (China)
CAR transgenic T cells
In Vitro Expanded Allogeneic Epstein–Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the




CD19 specific CAR expressed in allogeneic EBV
specific T cells
Phase 1 New York (USA)
EBV CTLs Expressing CD30 Chimeric Receptors For CD30+ Lymphoma (CARCD30)
(NCT01192464)
HD, NHL
CD30 specific CAR expressed in autologous EBV
specific T cells
Phase 1 Houston (USA)
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application (NCT02980315) NPC
LMP1 specific CAR expressed in autologous T
cells
Phase 1/2 Nanjing (China)
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (ATECRAB)
(NCT00709033)
CLL, NHL
CD19 specific CAR expressed in autologous EBV
specific T cells
Phase 1 Houston (USA)




CD30 specific CAR expressed in allogeneic EBV
specific T cells
Phase 1 Houston (USA)
CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) (CD19TPALL)
(NCT04288726)
ALL
CD19 specific CAR expressed in EBV specific





Phase I CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies
(NCT03233854)
DLBCL, ALL
CD19/CD22 specific CAR expressed in
autologous T cells
Phase 1 Palo Alto (USA)
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
(NCT03298828)
ALL, BL
CD19 specific CAR expressed on autologous
PD-1 knock-out T cells
Phase 1 Chongqing (China)
CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Hematological Malignancies
(NCT02443831)
ALL, BL
CD19 specific CAR expressed on autologous T
cells
Phase 1 London, Manchester (UK)
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent
or High-Risk Non-Hodgkin Lymphoma (NCT01815749)
NHL
CD19 specific CAR expressed in autologous T
cells
Phase 1 Duarte (USA)
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas,
Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
(NCT02153580)
NHL, CLL
CD19 specific CAR expressed in autologous T
cells
Phase 1 Duarte (USA)
Abbreviations: PTLD, post-transplant lymphoproliferative disease; NPC, nasopharyngeal carcinoma; ALL, acute lymphoblastic leukemia; HD, Hodgkin’s disease; NHL, non-Hodgkin
lymphoma; CLL, chronic lymphocytic leukemia; ENKTL, extranodal NK/T cell lymphoma; DLBLC, diffuse large B cell lymphoma; BL, Burkitt’s lymphoma.
Cells 2020, 9, 1400 8 of 13
However, these clinical trials have not yet reported results. Nevertheless, two strategies emerge to
provide TCR or CAR transgenic cellular products rapidly. This might be especially important for rapidly
progressing EBV associated malignancies, including PTLDs [88]. On the one hand, leukapheresis of
tumor patients is proposed, to harvest sufficient amounts of autologous T cells [89] for redirection with
CARs or EBV specific TCRs (Figure 3). On the other hand, allogeneic T cells might serve as a platform
for EBV+ tumor specific receptor expression, but these allogeneic T cells bear the danger of eliciting
graft-versus-host-disease (GvHD). However, it was noted that EBV specific T cells carry only low
alloreactivity [90], and are therefore favored as an allogeneic source in several clinical trials (Table 1).
Along these lines, allogeneic EBV specific T cells could be banked and transduced with either HLA
matched EBV specific TCRs, or tumor specific CARs, for infusion into patients with EBV associated
malignancies. As can be seen from the registered clinical trials, these sources of T cells are mainly
used for CAR transduction against EBV associated lymphomas, while EBV specific TCR transgenes
are mainly explored for EBV associated carcinomas, mainly NPC, for which no specific CARs exist
that would not cause severe side effects during treatment. Thus, both CAR and TCR transgenic T cell
therapies are currently explored to treat EBV associated malignancies.
Figure 3. In addition to autologous T cells that can be obtained from leukapheresis of the peripheral
blood of patients with EBV associated malignancies at sufficient numbers for TCR or chimeric antigen
receptors (CAR) transgenic T cell therapies, allogeneic T cells can be used, but their alloreactivity against
the recipient needs to be limited. EBV specific T cells that can be expanded from allogeneic T cells have
been found to carry only low alloreactivity and are used for clinical trials with CAR transgenic T cells.
This figure was created in part with modified Servier Medical Art templates, which are licensed under
a Creative Commons Attribution 3.0 unported license: https://smart.servier.com.
7. Conclusions and Outlook
Even though EBV specific T cell transfer, to treat virus associated malignancies, was one of the first
cellular therapies (more than 25 years ago [91]), we still have very limited knowledge as to which T cell
specificities and entities mediate this protective effect. While EBNA1, LMP1 and LMP2 have emerged
as suitable targets and have even been clinically tested [54,55], the recent realization that early lytic
EBV replication contributes to virus associated tumorigenesis provides additional antigens that could
be explored [7]. More than one EBV antigen might also be necessary for immunotherapy, because
any given T cell specificity seems to only target a subset of virus transformed cells at any given time.
Redirecting T cells by transgenic TCR expression to recognize EBV antigens should be better tolerated
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during treatment of lymphomas and leukemias than eliminating the whole B cell compartment with
CARs [81]. Therefore, similar as for adoptive T cell transfer therapy, EBV associated malignancies
could also pave the way for TCR transgenic T cell therapy, by targeting several viral antigens.
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